CD274 and esophageal squamous cell carcinoma: The emergence of immune checkpoint inhibitors (ICIs), specifically monoclonal antibodies targeting the PD-1/PD-L1 immune regulatory axis, has revolutionized therapeutic paradigms in advanced ESCC (2).